Overview

A Study of Anti-PD-1 (Pembrolizumab) + Hormonal Therapy in HR-positive Localized IBC Patients With Non-pCR to Neoadjuvant Chemotherapy

Status:
Not yet recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to learn if pembrolizumab in combination with standard hormone therapy can help to control and prevent inflammatory breast cancer (IBC). The safety of this drug combination will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab